Efficacy and possible mechanisms of action of Selank in generalized anxiety disorders and neurasthenia
Randomized study in people · 2008
- What was studied
- 62 patients; treatment-arm counts conflict between indexed abstract (30/32) and abridged reprint (42/20)
- Main finding
- The authors report similar anxiety changes with the two treatments and assess serum enkephalin metabolism.
Reported findings and study design
62 patients with generalized anxiety disorder or neurasthenia. Indexed abstract: Selank 30, medazepam 32.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Anxiety outcome | Similar changes reported | No numerical scale change supplied |
| Treatment-arm counts in an abridged reprint | 42 and 20 | Conflicts with the indexed 30/32 split |
The arm discrepancy is unresolved. The figures describe diagnostic groups. Treatment-group sizes are separate.
Source for these results ↗ · Reviewed 2026-10-29
Study limitations and source details
Study limitations
- Original journal version needed to resolve treatment-arm discrepancy. The 30 anxiety and 32 neurasthenia cases are diagnostic groups. Treatment-group sizes are separate.
- Allocation concealment and blinding remain unresolved.
- Active-comparator similarity does not establish noninferiority or long-term safety.
Source details
Journal publication · Indexed abstract plus abridged commercial-hosted reprint
Indexed abstract and branded-site abridged PDF methods checked. The PDF explicitly states it is shortened; it is not the complete original article.
Abstract and selected reprint methods; source discrepancy
Sources checked
Citation
A A Zozulia, G G Neznamov, T S Siuniakov, N V Kost, M V Gabaeva, O Iu Sokolov, E V Serebriakova, O A Siranchieva, A V Andriushenko, E S Telesheva, S A Siuniakov, A B Smulevich, N F Miasoedov, S B Seredenin. Efficacy and possible mechanisms of action of Selank in generalized anxiety disorders and neurasthenia Zh Nevrol Psikhiatr Im S S Korsakova. 108(4):38–48